Literature DB >> 20117266

Functional characterization of in vivo effector CD4(+) and CD8(+) T cell responses in acute Toxoplasmosis: an interplay of IFN-gamma and cytolytic T cells.

Erik Jongert1, Arnaud Lemiere, Jo Van Ginderachter, Stéphane De Craeye, Kris Huygen, Sushila D'Souza.   

Abstract

Development of prophylactic vaccines against Toxoplasma gondii is based on the observation that latently infected subjects are protected against secondary infection during pregnancy. Cocktail DNA vaccines have been shown to provide high resistance to parasite challenge, and latently infected mice are protected against acute disease. In order to characterize the associated Th1 cellular immune responses in vivo, we used H2-K(k) bone marrow macrophage cell lines constitutively expressing T. gondii GRA1, GRA7 or ROP2 antigens, for the in vivo characterization of antigen-specific T cells in an antigenic challenge model, and as target cells in an in vivo CTL assay. In latently infected C3H/HeN mice, CD4(+) and CD8(+) T cells were recruited to the peritoneal cavity after i.p. challenge with these syngeneic cell lines. GRA1 and GRA7-specific T cells from infected mice were IFN-gamma(+) FasL(-) CD107(-). No IFN-gamma or lytic markers were observed against ROP2. In cocktail DNA vaccinated C3H/HeN mice, the response was restricted to GRA1-specific CD8(+) IFN-gamma(-) FasL(-) CD107(+) T cells. Target cells expressing GRA1 and GRA7, but not ROP2, were efficiently killed in an in vivo CTL assay in latently infected mice, while in DNA vaccinated mice only lysis of GRA1 expressing target cells was observed. Both forms of immunization, DNA vaccination and latent infection, completely protected mice against acute Toxoplasmosis. The results obtained in this work suggest that distinct in vivo cytolytic effector mechanisms are at work in DNA vaccinated and latently infected mice, but both converge to protect against acute toxoplasmosis. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20117266     DOI: 10.1016/j.vaccine.2010.01.031

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Towards an immunosense vaccine to prevent toxoplasmosis: protective Toxoplasma gondii epitopes restricted by HLA-A*0201.

Authors:  Hua Cong; Ernest J Mui; William H Witola; John Sidney; Jeff Alexander; Alessandro Sette; Ajesh Maewal; Rima McLeod
Journal:  Vaccine       Date:  2010-11-21       Impact factor: 3.641

2.  Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route.

Authors:  Imran Rashid; Nathalie Moiré; Bruno Héraut; Isabelle Dimier-Poisson; Marie-Noëlle Mévélec
Journal:  Med Microbiol Immunol       Date:  2016-10-18       Impact factor: 3.402

3.  In vivo effect of anti-TNF agent (etanercept) in reactivation of latent toxoplasmosis.

Authors:  Nagwa Mostafa El-Sayed; Khadiga Ahmed Ismail; Abeer Fathy Badawy; Khaled Fathy Elhasanein
Journal:  J Parasit Dis       Date:  2015-09-24

4.  The polyomavirus BK large T-antigen-derived peptide elicits an HLA-DR promiscuous and polyfunctional CD4+ T-cell response.

Authors:  Bala Ramaswami; Iulia Popescu; Camila Macedo; Chunqing Luo; Ron Shapiro; Diana Metes; Geetha Chalasani; Parmjeet S Randhawa
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

5.  Toxoplasma gondii: immune response and protective efficacy induced by ROP16/GRA7 multicomponent DNA vaccine with a genetic adjuvant B7-2.

Authors:  Qi Liu; Fuwu Wang; Guan Wang; Qunli Zhao; Juan Min; Shuai Wang; Hua Cong; Ying Li; Shenyi He; Huaiyu Zhou
Journal:  Hum Vaccin Immunother       Date:  2013-10-07       Impact factor: 3.452

6.  A long-lasting protective immunity against chronic toxoplasmosis in mice induced by recombinant rhoptry proteins encapsulated in poly (lactide-co-glycolide) microparticles.

Authors:  Ying Xu; Nian-Zhang Zhang; Meng Wang; Hu Dong; Sheng-Yong Feng; Hui-Chen Guo; Xing-Quan Zhu
Journal:  Parasitol Res       Date:  2015-08-06       Impact factor: 2.289

7.  Protective efficacy of recombinant canine adenovirus type-2 expressing TgROP18 (CAV-2-ROP18) against acute and chronic Toxoplasma gondii infection in mice.

Authors:  Xiu-Zhen Li; Xiao-Hu Wang; Li-Jun Xia; Ya-Biao Weng; Jorge A Hernandez; Li-Qing Tu; Lu-Tao Li; Shou-Jun Li; Zi-Guo Yuan
Journal:  BMC Infect Dis       Date:  2015-03-04       Impact factor: 3.090

8.  Compound DNA vaccine encoding SAG1/ SAG3 with A2/B subunit of cholera toxin as a genetic adjuvant protects BALB/c mice against Toxoplasma gondii.

Authors:  Hua Cong; Min Zhang; Qing Xin; Zhiyu Wang; Ying Li; Qunli Zhao; Huaiyu Zhou; Shenyi He
Journal:  Parasit Vectors       Date:  2013-03-13       Impact factor: 3.876

9.  Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles.

Authors:  Shu-Chun Chuang; Jing-Chun Ko; Chaio-Ping Chen; Jia-Tze Du; Chung-Da Yang
Journal:  Parasit Vectors       Date:  2013-02-11       Impact factor: 3.876

10.  Toxoplasma gondii protein disulfide isomerase (TgPDI) is a novel vaccine candidate against toxoplasmosis.

Authors:  Hai-Long Wang; Ya-Qing Li; Li-Tian Yin; Xiao-Li Meng; Min Guo; Jian-Hong Zhang; Hong-Li Liu; Juan-Juan Liu; Guo-Rong Yin
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.